You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Investigational Drug Information for PF-04457845


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for PF-04457845?

PF-04457845 is an investigational drug.

There have been 10 clinical trials for PF-04457845. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Marijuana Abuse, Syndrome, and Osteoarthritis, Knee. The leading clinical trial sponsors are Pfizer, Yale University, and National Institute on Drug Abuse (NIDA).

Recent Clinical Trials for PF-04457845
TitleSponsorPhase
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)Columbia UniversityPhase 2
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)Johns Hopkins UniversityPhase 2
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)Medical University of South CarolinaPhase 2

See all PF-04457845 clinical trials

Clinical Trial Summary for PF-04457845

Top disease conditions for PF-04457845
Top clinical trial sponsors for PF-04457845

See all PF-04457845 clinical trials

PF-04457845: A Promising FAAH Inhibitor for Various Indications

Introduction

PF-04457845 is a potent and selective irreversible fatty acid amide hydrolase (FAAH) inhibitor that has garnered significant attention for its potential in treating a range of medical conditions, including post-traumatic stress disorder (PTSD), osteoarthritis, and psychiatric illnesses. Here, we delve into the development updates and market projections for this drug candidate.

Mechanism of Action

PF-04457845 works by inhibiting FAAH, an enzyme responsible for the breakdown of endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG). By preventing the degradation of these endocannabinoids, PF-04457845 increases their levels in the body, which can have therapeutic effects on various conditions[2][4].

Development History

PF-04457845 was initially developed by Pfizer and later licensed to SpringWorks Therapeutics in 2017. In October 2020, Jazz Pharmaceuticals acquired the FAAH inhibitor program, including PF-04457845, from SpringWorks Therapeutics. This acquisition included an upfront payment of $35 million and potential milestone payments of up to $375 million, along with tiered royalties on future net sales[1][3].

Clinical Trials and Efficacy

PF-04457845 has undergone Phase 1 testing in humans and has been found to be safe and effective in elevating AEA levels without producing notable adverse events, including psychoactivity and euphoria associated with THC. The compound has shown promising activity in populations relevant to PTSD, such as fear extinction in healthy volunteers and anxiety symptoms in cannabis use disorder[1][4].

PTSD and Psychiatric Conditions

Jazz Pharmaceuticals is currently focusing on developing PF-04457845 for the treatment of PTSD and associated symptoms. The drug represents an innovative approach to treating PTSD by addressing multiple core symptoms, including fear extinction, anxiety, and disrupted sleep architecture[1].

Other Indications

In addition to PTSD, PF-04457845 is being evaluated for several other indications, including osteoarthritis, cannabis use disorder, acute and chronic pain, and Tourette syndrome. Although it was found ineffective in treating osteoarthritic pain, its potential in psychiatric conditions remains a significant area of interest[5].

Market Projection

The market for FAAH inhibitors, while not robust, holds promise due to the unique mechanism of action and the potential to address unmet medical needs in psychiatric and pain disorders.

Competitive Landscape

The FAAH inhibitor pipeline is relatively thin, with only a few active products, none of which are in late-stage (Phase III) development. Key players like Janssen and SpringWorks Therapeutics have been involved in Phase II trials, although some programs have been suspended or abandoned due to inefficacy or strategic reasons[5].

Market Potential

Given the lack of effective treatments for conditions like PTSD and the growing interest in the endocannabinoid system as a therapeutic target, PF-04457845 has significant market potential. If successful in clinical trials and subsequent regulatory approvals, it could become a life-changing medicine for patients with inadequate responses to current therapies.

Financial and Regulatory Aspects

The acquisition by Jazz Pharmaceuticals includes substantial financial commitments, with potential milestone payments and royalties that could significantly benefit SpringWorks Therapeutics if the drug meets clinical, regulatory, and commercial milestones. This financial backing is crucial for advancing the drug through the development pipeline[1][3].

Challenges and Future Directions

While PF-04457845 shows promise, it faces challenges common to many drug development programs, including the need for successful clinical trials and regulatory approvals. The drug's safety profile and efficacy in larger patient populations will be critical factors in its future success.

Key Takeaways

  • Mechanism of Action: PF-04457845 is a potent and selective irreversible FAAH inhibitor.
  • Development Status: Acquired by Jazz Pharmaceuticals from SpringWorks Therapeutics, with a focus on PTSD treatment.
  • Clinical Trials: Phase 1 trials have shown safety and efficacy; ongoing development for PTSD and other indications.
  • Market Potential: Significant potential due to unmet medical needs in psychiatric and pain disorders.
  • Financial Aspects: Substantial financial commitments including milestone payments and royalties.

FAQs

What is PF-04457845?

PF-04457845 is a potent and selective irreversible fatty acid amide hydrolase (FAAH) inhibitor.

What conditions is PF-04457845 being evaluated for?

PF-04457845 is being evaluated for PTSD, osteoarthritis, cannabis use disorder, acute and chronic pain, and Tourette syndrome.

Who currently owns the rights to PF-04457845?

Jazz Pharmaceuticals owns the rights to PF-04457845 after acquiring it from SpringWorks Therapeutics in 2020.

What is the current stage of clinical development for PF-04457845?

PF-04457845 has completed Phase 1 trials and is currently in development for various indications, with a focus on PTSD.

What are the potential financial benefits for SpringWorks Therapeutics from this deal?

SpringWorks Therapeutics could receive up to $375 million in milestone payments and tiered royalties on future net sales of PF-04457845.

Sources

  1. Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program. PR Newswire, 26 Oct 2020.
  2. PF 04457845 | Fatty Acid Amide Hydrolase (FAAH) Inhibitors. R&D Systems.
  3. SpringWorks Therapeutics, Inc.. Investor Relations, 12 Nov 2020.
  4. The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. Cambridge University Press, 6 Sep 2023.
  5. FAAH (Fatty Acid Amide Hydrolase Inhibitor). DelveInsight, 22 Jun 2018.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.